Close menu




November 16th, 2022 | 13:30 CET

BioNTech, Meta Materials, and Amazon - Industry leaders belong in the portfolio

  • metamaterials
  • Technology
  • Biotechnology
  • ecommerce
Photo credits: pixabay.com

In 2021, the stock market world was still in order - it had been going nowhere but up for years. That was the peak of the stock hype, and many top dogs in their industries were very expensive from a fundamental point of view. That has changed significantly this year. Due to the Ukraine conflict, rising interest rates and ever-higher inflation, many industry leaders had to make significant losses. Even a drop of 50% was not uncommon. Yet the long-term outlook is good. Now that the stock market is slowly regaining momentum, it is worth taking a look at three companies that are leaders in their field.

time to read: 4 minutes | Author: Armin Schulz
ISIN: Meta Materials Inc. | US59134N1046 , AMAZON.COM INC. DL-_01 | US0231351067 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    BioNTech - Full pipeline

    BioNTech is a leader in the field of corona vaccines. The Mainz-based Company was the first to bring a vaccine to market with its mRNA technology. Since then, the active ingredient Comirnaty has been the Company's cash cow. News surrounding corona protection continues to largely dominate the news, such as on November 10, when the CHMP issued a recommendation for booster vaccination against the Omicron BA.4/BA.5 variant for children ages 5 to 11. On November 14, the Company purchased a manufacturing facility from Novartis in Singapore. In the future, mRNA vaccines for the Asian market will be produced there.

    But the Mainz-based company has long been working on the next blockbuster. It is investing the profits from vaccine production in the development of new therapy options, including against cancer. As early as 2023, there should be up to 10 results from the ongoing studies. A look at the Q3 numbers shows that both revenues and profits are down. After the Corona situation calmed down, demand declined. In the last quarter, revenues were around EUR 3.5 billion, with profits of around EUR 1.8 billion. Nevertheless, management expects to achieve the forecasts or end up at the upper end of the range. The Company has high hopes for the new Omicron vaccine.

    Since October 21, the share price has started to form an upward trend. Currently, the stock is trading at EUR 154.15. Following the quarterly figures, analysts at Goldman Sachs have issued a Hold rating with a price target of USD 177. Berenberg, on the other hand, takes a much more positive view of the share and has issued a Buy recommendation with a price target of USD 312. Positive study results are already priced in here. The road to the finished product is still long in the case of cancer vaccines. The Company is making the most progress with the flu vaccine, where the clinical trial is already in phase 3.

    Meta Materials - Growth continues in the 3rd quarter

    Meta Materials has managed to transfer high-performance functional materials and nanocomposites (metamaterials) from the laboratory to mass production using a roll-to-roll process. This significantly reduces the cost to a few dollars per square meter. The metamaterials are given properties that they do not naturally have. Depending on customer requirements, samples are developed using artificial intelligence. As a result, customer-specific solutions can be created within days. The application areas are broadly diversified and range from 5G to electric vehicles, medicine, Internet-of-Things, energy and aerospace.

    On November 1, a collaboration with DuPont Teijin Films and Mitsubishi Electric Europe was announced with the goal of a safer and more efficient lithium-ion battery. In the process, Meta Materials' PLASMAfusion copper foil is said to reduce weight and cost. At the same time, the battery's energy efficiency, range and safety are to be increased. That is just one megatrend that could benefit from Meta Materials patents. The Company's Q3 numbers also show that it is making progress in commercializing its technologies. Revenue increased 329% YOY to USD 2.45 million. For the first 9 months, revenues climbed as much as 388%. However, the Company is still in the red due to its investments. There was a loss of USD 0.07 per share.

    On the other hand, the Company owns 292 granted patents. A total of 472 patents are currently filed. The customer and partner list is also impressive. It includes illustrious names such as Samsung, Sony, Panasonic, Airbus, Boeing, Mitsubishi Electric, Mazda, Covestro and many more. A company presentation can be found on the International Investment Forum YouTube channel. The stock, which once traded at USD 21.76 last year due to Facebook's renaming to Meta, was under pressure until early October, marking its low at USD 0.63. Subsequently, it went up more than 180%. Currently, one pays USD 1.69 for a share certificate. Even a single breakthrough should lead to a revaluation of the share.

    Amazon - Job cuts and cost reduction

    Amazon is the top dog in e-commerce. In the beginning, Amazon mainly shipped books, but today the online giant offers almost everything. In addition, the product range is constantly being expanded. The Prime subscription model gives users free shipping and access to PrimeVideo, the streaming platform, PrimeReading, Amazon Music, PrimeGaming and other features. Most recently, many e-commerce companies suffered significant losses as rising inflation and recession fears dampened consumer sentiment significantly.

    Experts believe the e-commerce sector will continue to grow slower than during the pandemic. According to various media reports, Amazon will cut around 10,000 jobs. Amazon wants to cut costs and thus begin to improve its numbers. Amazon already expects a weak 4th quarter due to clouded consumer behavior. But there are not only savings. Currently, a virtual health service called AmazonClinc is being tested in 32 states in the US.

    As the industry leader, Amazon is expected to gain further market share. Whether this will dispel investor skepticism remains to be seen. At its peak, the stock has lost almost 50% since the beginning of the year. The low was USD 85.87. Currently, the share is climbing and is now at USD 103. After the last quarterly figures, in which the profit declined although sales increased, there were hailings of buy recommendations for the stock from Credit Suisse, RBC and Jeffries. The price targets are between USD 135 and USD 142. Thus, the share has a good 30% upside potential.


    All three companies are industry leaders. While Amazon and BioNTech are already making money, the growth company Meta Materials is still in the red, but sales are already rising sharply. A single breakthrough should take the share into the black. Meta Materials is an interesting portfolio addition next to the established industry leaders.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Armin Schulz on November 30th, 2022 | 10:57 CET

    Alibaba, Kleos Space, Plug Power - Turnaround candidates with potential

    • Space
    • ecommerce
    • Energy
    • Satellites

    In the wake of the recent stock market rally, some stocks have fallen behind. While the market has been optimistic about the future of some stocks, others have not had the same success. For investors looking for a potential turnaround stock, we have picked three companies worth considering. Each company has its own challenges and opportunities, and investors should do their due diligence before investing. With the right timing and strategy, these companies could be well poised for a comeback in the not-too-distant future.

    Read